Royalty Pharma (RPRX) Bank of America Global Healthcare Conference 2026 summary

Market landscape and competitive positioning

• Confident in market position, citing three major transactions this year, including innovative phase III financing deals with J&J and Teva, and a traditional royalty from Zymeworks on a Jazz oncology product.

• Market for royalty financing is expanding, with increasing demand from large pharma and new geographies like China.

• Competition has expanded the market and validated the royalty model, with no loss of competitive edge.

Growth drivers and strategic focus

• Core biopharma market is growing, with rising capital needs and increased M&A activity.

• Pharma R&D partnerships, China expansion, and pipeline maturation are key growth pillars for the next three years.

• Recent successes in the unapproved pipeline are expected to become more visible growth contributors.

Operational scaling and talent strategy

• Headcount has tripled since IPO, with targeted growth focused on research and data teams.

• New head of AI hired to enhance research capabilities and investment diligence.

• Recent senior hire from Bank of America to strengthen deal flow and relationships.